Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Magdi Elsallab, M.D.,Ph.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov. 2021 Sep; 2(5):408-422. PMID: 34568831.
    Citations: 21     Fields:    Translation:HumansCells
  2. Thieme CJ, Abou-El-Enein M, Fritsche E, Anft M, Paniskaki K, Skrzypczyk S, Doevelaar A, Elsallab M, Brindle N, Blazquez-Navarro A, Seibert FS, Meister TL, Pfaender S, Steinmann E, Witzke O, Westhoff TH, Stervbo U, Heine G, Roch T, Babel N. Detection of SARS-CoV-2-specific memory B cells to delineate long-term COVID-19 immunity. Allergy. 2021 08; 76(8):2595-2599. PMID: 33764510.
    Citations: 3     Fields:    Translation:HumansCells
  3. Elsallab M, Bravery CA, Kurtz A, Abou-El-Enein M. Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals. Mol Ther Methods Clin Dev. 2020 Sep 11; 18:269-279. PMID: 32637456.
    Citations: 16     
  4. Elsallab M, Levine BL, Wayne AS, Abou-El-Enein M. CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol. 2020 02; 21(2):e104-e116. PMID: 32007196.
    Citations: 31     Fields:    Translation:Humans
  5. Kurtz A, Elsallab M, Sanzenbacher R, Abou-El-Enein M. Linking Scattered Stem Cell-Based Data to Advance Therapeutic Development. Trends Mol Med. 2019 01; 25(1):8-19. PMID: 30497944.
    Citations: 1     Fields:    Translation:HumansCells
  6. Bauer G, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018 09; 7(9):676-685. PMID: 30063299; PMCID: PMC6127222.
    Citations: 45     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Elsallab's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (21)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.